Mitchell E. Gross, MD, PhD

Associate Professor of Clinical Medicine

Image of Mitchell E. Gross, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Awards

  • Phi Beta Kappa, 1989
  • UCSD/Revelle College Academic: Leadership Award, 1990
  • Alpha Omega Alpha, 1994
  • Hewlett Packard Award for Excellence in Internal Medicine, 1994
  • Specialty Training Advanced Research Fellowship, 1997
     – 2002
  • Amgen Fellowship Research Award, 1999
  • Rhone Phoulenc Rorer Travel Award, 1999
  • AACR-AFLAC Scholar in Training Award,, 2001
  • Donna and Jesse Garber Award, 2006

Research Funding

  • Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH · R21EB022932 · Sep 16, 2016 – Jul 31, 2018 · Role: Co-Principal Investigator
  • Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH · K08DK064379 · Aug 21, 2002 – Jun 30, 2007 · Role: Principal Investigator

Publications

  • Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 04; 24(4):157-170.. View in PubMed
  • A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis. 2016 12; 19(4):323-332.. View in PubMed
  • Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med. 2015 Sep 14; 13:219.. View in PubMed
  • Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7.. View in PubMed
  • Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758.. View in PubMed
  • A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. Prostate. 2015 Jun; 75(8):863-71.. View in PubMed
  • Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol. 2015 Nov; 33(11):1669-76.. View in PubMed
  • Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; e270-3. Dorff TB, Gross ME . View in PubMed
  • A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65.. View in PubMed
  • Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777.. View in PubMed